Is There a Treatment for BPD?

Size: px
Start display at page:

Download "Is There a Treatment for BPD?"

Transcription

1 Is There a Treatment for BPD? Amir Kugelman, Pediatric Pulmonary Unit and Department of Neonatology Bnai Zion Medical Center, Rappaport Faculty of Medicine Haifa, Israel

2 Conflict of Interest Our study was not funded. Teva supplied the QVAR and placebo, Trupharm supplied the Aerochambers.

3 BPD: Treatment??? Prevention Treatment

4 Antenatal Steroids and Poor Neonatal Outcome Rates (Kugelman et al. Arch of Pediatrics and Adolescent Medicine 2012) Combined poor outcome of death or severe morbidity by prenatal steroid therapy. Prenatal steroids and BPD - contervertial

5 Baud O, et al. Lancet. 2016

6 Baud O et al. Lancet. 2016

7 Bassler DN. NEUROSIS Trial Group. NEJM. 2015

8 No Magic Bullet Comprehensive Strategy to Prevent BPD Delivery Room or NICU Neopuff Endotracheal Intubation Caffeine INSURE Approach Surfactant Steroids- Selective use Nutrition Vitamin A? Immediate Extubation Extubation at RDS Resolution HFNC MIST NCPAP Nasal Respiratory Support Nasal Ventilation (NIPPV/SNIPPV) NAVA 1Permissive Hypercapnia 2Adequate Oxygenation Spontaneous Unsupported Breathing (Kugelman A. Ped Pulmonol 2011)

9 BPD: Treatment? Prevention Comprehensive approach Treatment

10 Introduction The evidence supporting inhaled steroids in spontaneously breathing infants with BPD is limited, and based on only two RCT with relative small number of infants (Cochrane, 2010). The Cochrane review concluded that these studies do not allow firm conclusions with regard to the efficacy of inhaled steroids in non-ventilated infants (Lister P et al. Cochrane 2010).

11 Introduction The "new" BPD involves the lungs more than the airways and is characterized by: Fewer but larger alveoli, Mild fibrosis, Persistent inflammation (Am J Respir Crit Care Med. 2003; Jobe AH. Am J Respir Crit Care Med. 2001, Jobe AH. Curr Opin Pediatr 2011).

12 Utilization of Inhaled Corticosteroids for Infants with BPD (Slaughter et al. PLoS One 2014) Retrospective Cohort Study. Evolving BPD. 15 US NICU Inhaled corticosteroid administration to infants with BPD is common in U.S. NICUs. Varies markedly between centers. This supports the need for further research.

13 Introduction Thus, there is a need to ascertain the role of inhaled steroids in infants with "new" BPD. Recent studies demonstrated the potential role of early use of systemic (Baud O et al. Lancet. 2016) or inhaled steroids in the prevention of "new" BPD (Bassler D, et al; N Engl J Med. 2015).

14 Introduction QVAR (extra-fine hydrofluoalkane-beclomethasone dipropionate [HFA-BDP]) is a new inhaled corticosteroid that is unique in its small particle size (1.1 micron) (Leach et al. Chest. 2002; de Vries et al. Respir Med. 2009). This results in higher lung deposition of QVAR (Devadason SG et al. Eur Respir J. 2003), and permits a reduction in the dosage relative to CFC-BDP (Vanden Burgt JA et al. J Allergy Clin Immunol. 2000).

15 Introduction These characteristics of the QVAR led to studies in models of ventilated and spontaneously breathing infants: Small airways, Obligatory nose breathers, Irregular breathing patterns. The studies showed better lung deposition of QVAR compared to CFC-BDP (Janssens HM et al. Chest. 2003; Cole CH et al. Arch Dis Child Fetal Neonatal Ed ).

16 Introduction Compared with other inhaled steroids in asthma QVAR was found to be: At least as effective as or better Demonstrated similar safely profile (Fireman P et al. Ann Allergy Asthma Immunol. 2001; Worth H et al. Respiration. 2001; Price D et al. J Allergy Clin Immunol. 2010).

17 Study Aim To determine if inhaled QVAR will be effective in Reducing respiratory rehospitalizations Respiratory morbidities (within the NICU and 3 month post discharge) In infants with established moderate/ severe BPD compared with placebo.

18 Methods: Study Design This was a double blind, randomized placebocontrol, multi-center pilot study conducted at five university affiliated NICUs in Israel. (Meir, Ashkelon, Haemek, Laniado, Bnai Zion). The study was approved by the ethics committee of the Israeli Ministry of Health.

19 Methods: Study Design Our primary outcome measure was: To compare the rate of respiratory readmissions to the hospital during the study period between the QVAR and placebo groups. Secondary outcomes measures: Comparison of clinical, growth and safety parameters.

20 Methods: Patients Inclusion Criteria 1) Preterm infants (born <32 weeks) with moderate to severe BPD, - Moderate: O 2 <30% - Severe: O 2 >30% or with positive pressure support - At 36 weeks corrected gestational age, (Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001), 2) Parents signed an informed consent.

21 Methods: Patients Exclusion Criteria 1) Congenital malformation. 2) Unstable infants (Cardiac, neurological, or sepsis). 3) Unavailable F/U.

22 Methods: Study Procedure Eligible infants were randomized to Inhaled QVAR 100 microgram or Placebo Twice daily via Aerochamber with face mask (Neonatal Chamber, Trudell Medical International, London, ON, Canada). Treatment was given daily until 3 months post discharge.

23 Methods: Study Procedure Follow up visits were done at: Randomization Discharge Once a month until the end of the study. Patients were allowed to get other medication according to the decision of the attending Neonatologist or Pediatrician.

24 Methods: Study Procedure If the treating physician decided to add inhaled steroids during BPD exacerbation, he was allowed to give inhaled fluticasone, 125 microgram via Aerochamber twice daily until the exacerbation resolved. Oxygen was administered to keep pulse oximetry between 90-95%, and was stopped according to the treating Neonatologist. Analysis was done by intention to treat.

25 Results

26 Excluded 3 ½ months of systemic steroids Infants Enrollment QVAR n = 18 Discharge home Eligible Infants with moderate to severe BPD n=47 Included infants n = 38 Placebo n = 20 Included infants Infants excluded from the study n=9 Parental refusal = 4 Instability (Neurological, Cardiac ) = 4 Social problem = 1 Death before discharge n = 1 Lost in 2 nd month f/u n = 2 3 rd month f/u n = 1 n = 17 Finalized 3 months active follow up n = 14 n = 19 Finalized 3 months active follow up n = 19

27 Infants Characteristics

28 Infants Characteristics

29 Figure 2 A Rehospitalizations (days) P= QVAR Placebo B Rehospitalizations / infant P= QVAR Placebo C Additive Steroids (days) P=0.63 P=1.00 P= Qvar Placebo Qvar Placebo Qvar Placebo Inhaled Steroids Systemic Steroids Inhaled Steroids or Systemic Steroids

30 Clinical Outcomes P = 0.796

31 Clinical and Safety Outcomes Out of the QVAR group: 1 infant was admitted to PICU for Parainfluenzae bronchiolitis Out of the placebo group: 1 infant died before discharge (sepsis), 2 infants were admitted to PICU for bronchiolitis (RSV and Parainfluenzae). Season at discharge: No significant difference study vs. placebo. There was no significant difference between the groups in urine cortisol/creatinine ratio at recruitment or at study end. No adrenal supresion.

32 Discussion Our study was unable to detect a significant effect of inhaled QVAR vs. placebo on the respiratory course of established BPD until discharge or during the following 3 months period. Rate of rehospitalizations, Use of oxygen ( vs days, NS) Tended to be lower in the QVAR group.

33 Discussion Our results may suggest modest benefits of QVAR that our study did not have the power to confirm (type II error). At the same time, there was a tendency towards higher use of additional steroids post discharge in the placebo group. This could mask possible benefits of QVAR. It is also possible that inhaled steroids, have no effect on established moderate/severe BPD.

34 Discussion Current Literature Yuksel et al (Thorax. 1992) in a prospective, cross over, randomized double-blind study treated 18 infants with BPD (???-wheezy preterm infants month of age) with inhaled 200 microgram twice daily of chlorofluocarbon-beclomethasone dipropionate (CFC-BDP) via spacer and face mask for 6 weeks. They found in the treatment vs. the placebo group. 37% reduction in symptom score, Increase in bronchodilator free days Increase in functional residual capacity

35 Discussion Current Literature Beresford et al (Arch Dis Child Fetal Neonatal Ed. 2002), in a double blind prospective study that included 15 infants in each arm, treated with fluticasone 250 microgram twice daily vs. placebo for a year, found: No benefit with the treatment in terms of day or night symptoms (cough or wheeze). Treatment was safe in both studies. Early study termination: difficulty in recruitment

36 Fluticasone Inhalation in Moderate Cases of BPD (Dugas et al. Pediatrics 2005) 32 infants, moderate BPD were aged between 28 and 60 days were randomized. Fluticasone 125 mic twice daily for 3 weeks and once daily for a fourth week was delivered to infants who weighed between 500 and 1200 g. The dosage was doubled for infants who weighed >1200 g.

37 (Dugas et al. Pediatrics 2005) Results: No effect on duration of supplemental O 2 therapy. of ventilatory support. Conclusions: Fluticasone did not affect: - Supplemental O 2 use - Need for ventilatory support. However, fluticasone lowered chest radiograph scores. Trends on BP, adrenal supresion. Conclusion: The results of this investigation do not support the use of inhaled corticosteroids in the treatment of oxygen-dependent infants who have established moderate BPD.

38 Short-term Adverse Reactions We detected no short-term adverse reactions, Weight and height gain, Blood pressure Urine cortisol/creatinine ratio Comparable between the QVAR and the placebo groups. The placebo group tended to receive higher dose of additive steroids (flixotide), thus possible adverse effects of QVAR, could be obscured.

39 Study Strength Design: RCT double blind, multi-center study. Clinical significance Originality: New BPD, QVAR for BPD

40 Study Limitations Our study was underpowered. Relative short prospective F/U. No objective PFTs. Infants in the control group were allowed, and tended to receive more inhaled or systemic steroids, just masking a possible positive effect of QVAR.

41 Conclusions Our study was unable to detect a significant effect of inhaled QVAR vs. placebo on the respiratory course of established BPD. The study was underpowered.

42 Conclusions Possible benefits of QVAR could be masked by a tendency towards higher use of additional steroids in the placebo group. We detected no short-term adverse reactions. Our study is important for: Future RCT design on QVAR in established BPD Future meta-analyses.

43 Clinical Implications Currently, we cannot rule out or affirm whether inhaled steroids should be administered routinely. Inhaled steroids may be tried on individualized basis and continued according to the clinical response within 2-4 weeks.

44 BPD: Treatment? Prevention Comprehensive approach Treatment Not yet

45 Thank You All participating centers Parents

Kugelman A, Riskin A, Said W, Shoris I, Mor F, Bader D.

Kugelman A, Riskin A, Said W, Shoris I, Mor F, Bader D. Heated, Humidified High-Flow Nasal Cannula (HHHFNC) vs. Nasal Intermittent Positive Pressure Ventilation (NIPPV) for the Primary Treatment of RDS, A Randomized, Controlled, Prospective, Pilot Study Kugelman

More information

Noah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018

Noah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018 Postnatal Steroids Use for Bronchopulmonary Dysplasia in 2018 + = Noah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018 AAP Policy Statement - 2002 This statement is intended for

More information

AEROSURF Phase 2 Program Update Investor Conference Call

AEROSURF Phase 2 Program Update Investor Conference Call AEROSURF Phase 2 Program Update Investor Conference Call November 12, 2015 Forward Looking Statement To the extent that statements in this presentation are not strictly historical, including statements

More information

Chronic Lung Disease Of Prematurity. Dr Jo Harrison

Chronic Lung Disease Of Prematurity. Dr Jo Harrison Chronic Lung Disease Of Prematurity Dr Jo Harrison 9.9.14 Chronic Neonatal Lung Disease Bronchopulmonary dysplasia (BPD) first described in 1967 by Northway Defined as O 2 dependence at 28 days post birth

More information

Non-Invasive PCO 2 Monitoring in Infants Hospitalized with Viral Bronchiolitis

Non-Invasive PCO 2 Monitoring in Infants Hospitalized with Viral Bronchiolitis Non-Invasive PCO 2 Monitoring in Infants Hospitalized with Viral Bronchiolitis Gal S, Riskin A, Chistyakov I, Shifman N, Srugo I, and Kugelman A Pediatric Department and Pediatric Pulmonary Unit Bnai Zion

More information

McMASTER NICU INHALED STEROIDS FOR EVOLVING BPD (GA < 29 WEEKS)

McMASTER NICU INHALED STEROIDS FOR EVOLVING BPD (GA < 29 WEEKS) McMASTER NICU INHALED STEROIDS FOR EVOLVING BPD (GA < 29 WEEKS) Developed by: Amit Mukerji, Samira Samiee-Zafarghandy, Jennifer Twiss, Ereny Bassilious, Elizabeth Vo, Shari Gray, Salhab el Helou on behalf

More information

An Overview of Bronchopulmonary Dysplasia and Chronic Lung Disease in Infancy

An Overview of Bronchopulmonary Dysplasia and Chronic Lung Disease in Infancy An Overview of Bronchopulmonary Dysplasia and Chronic Lung Disease in Infancy Housekeeping: I have no financial disclosures Learning objectives: Develop an understanding of bronchopulmonary dysplasia (BPD)

More information

Respiratory Management and Outcome of Preterm Infants

Respiratory Management and Outcome of Preterm Infants Respiratory Management and Outcome of Preterm Infants 6 th Annual Care Of The Sick Newborn Conference Shu Wu, MD. Department of Pediatrics Division of Neonatology University of Miami School of Medicine

More information

Hydrofluoroalkane- vs Chlorofluorocarbon-Beclomethasone Delivery in Neonatal Models. Tufts University School of Medicine, Boston, MA, and

Hydrofluoroalkane- vs Chlorofluorocarbon-Beclomethasone Delivery in Neonatal Models. Tufts University School of Medicine, Boston, MA, and Hydrofluoroalkane- vs Chlorofluorocarbon-Beclomethasone Delivery in Neonatal Models Cynthia H. Cole, MD, MPH 1, Jolyon P. Mitchell, PhD 2, Martin P. Foley 2, and Mark W. Nagel, HBSC 2 1 The Floating Hospital

More information

BRONCHOPULMONARY DYSPLASIA

BRONCHOPULMONARY DYSPLASIA BRONCHOPULMONARY DYSPLASIA CHRONIC NEONATAL LUNG DISEASE (CLD) 2 2 nd BERLIN NEONATOLOGY SUMMER SCHOOL September 2014 3 Mt. Scopus 4 Ein Kerem 5 BRONCHOPULMONARY DYSPLASIA 1960: Ventilation of Neonates

More information

Dr. AM MAALIM KPA 2018

Dr. AM MAALIM KPA 2018 Dr. AM MAALIM KPA 2018 Journey Towards Lung protection Goals of lung protection Strategies Summary Conclusion Before 1960: Oxygen; impact assessed clinically. The 1960s:President JFK, Ventilators mortality;

More information

Non Invasive Ventilation In Preterm Infants. Manuel Sanchez Luna Hospital General Universitario Gregorio Marañón Complutense University Madrid

Non Invasive Ventilation In Preterm Infants. Manuel Sanchez Luna Hospital General Universitario Gregorio Marañón Complutense University Madrid Non Invasive Ventilation In Preterm Infants Manuel Sanchez Luna Hospital General Universitario Gregorio Marañón Complutense University Madrid Summary Noninvasive ventilation begings in the delivery room

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE 1 Guideline title SCOPE Bronchiolitis: diagnosis and management of bronchiolitis in children. 1.1 Short title Bronchiolitis in children 2 The remit The

More information

Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence

Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children

More information

Objectives. Apnea Definition and Pitfalls. Pathophysiology of Apnea. Apnea of Prematurity and hypoxemia episodes 5/18/2015

Objectives. Apnea Definition and Pitfalls. Pathophysiology of Apnea. Apnea of Prematurity and hypoxemia episodes 5/18/2015 Apnea of Prematurity and hypoxemia episodes Deepak Jain MD Care of Sick Newborn Conference May 2015 Objectives Differentiating between apnea and hypoxemia episodes. Pathophysiology Diagnosis of apnea and

More information

Hazards and Benefits of Postnatal Steroids. David J. Burchfield, MD Professor and Chief, Neonatology University of Florida

Hazards and Benefits of Postnatal Steroids. David J. Burchfield, MD Professor and Chief, Neonatology University of Florida Hazards and Benefits of Postnatal Steroids David J. Burchfield, MD Professor and Chief, Neonatology University of Florida Disclosures I have no financial affiliations or relationships to disclose. I will

More information

Rango de saturacion de oxigeno: Cual es la evidencia?

Rango de saturacion de oxigeno: Cual es la evidencia? Rango de saturacion de oxigeno: Cual es la evidencia? Wally Carlo, M.D. University of Alabama at Birmingham Department of Pediatrics Division of Neonatology wcarlo@peds.uab.edu 1 2 Stevie Wonder 4 Objectives

More information

Management of wheeze in pre-school children. Prof Colin Robertson, Respiratory Medicine, Royal Children s Hospital, Melbourne

Management of wheeze in pre-school children. Prof Colin Robertson, Respiratory Medicine, Royal Children s Hospital, Melbourne Management of wheeze in pre-school children Prof Colin Robertson, Respiratory Medicine, Royal Children s Hospital, Melbourne General Practitioner encounters for asthma Asthma in Australia, 2003 Emergency

More information

NEONATAL NEWS Here s Some More Good Poop

NEONATAL NEWS Here s Some More Good Poop NEONATALNEWS Here ssomemoregoodpoop WINTEREDITION2010 THISNEWSLETTERISPUBLISHEDPERIODICALLYBYTHENEONATOLOGISTSOF ASSOCIATESINNEWBORNMEDICINETOCONVEYNEWANDUPDATEDPOLICIES ANDGUIDELINESANDPROVIDEGENERALEDUCATIONTONICUCARETAKERSAT

More information

Predicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa

Predicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising

More information

Name and title of the investigators responsible for conducting the research: Dr Anna Lavizzari, Dr Mariarosa Colnaghi

Name and title of the investigators responsible for conducting the research: Dr Anna Lavizzari, Dr Mariarosa Colnaghi Protocol title: Heated, Humidified High-Flow Nasal Cannula vs Nasal CPAP for Respiratory Distress Syndrome of Prematurity. Protocol identifying number: Clinical Trials.gov NCT02570217 Name and title of

More information

Practical Approach to Managing Paediatric Asthma

Practical Approach to Managing Paediatric Asthma Practical Approach to Managing Paediatric Asthma Dr Andrew Tai FRACP, PhD Paediatric Respiratory and Sleep Specialist Women's and Children's Hospital, Adelaide Approaching the patient Check the diagnosis

More information

Quality Improvement Approaches to BPD. Jay P. Goldsmith, M.D. Tulane University New Orleans, Louisiana

Quality Improvement Approaches to BPD. Jay P. Goldsmith, M.D. Tulane University New Orleans, Louisiana Quality Improvement Approaches to BPD Jay P. Goldsmith, M.D. Tulane University New Orleans, Louisiana goldsmith.jay@gmail.com No conflicts of interest to declare There is nothing more dangerous to the

More information

Best Practices in Bronchopulmonary

Best Practices in Bronchopulmonary Best Practices in Bronchopulmonary Dysplasia a (BPD) Prevention e Matthew M. Laughon, MD, MPH Professor of Pediatrics The University of North Carolina at Chapel Hill I receive support from the U.S. government

More information

PAEDIATRIC RESPIRATORY FAILURE. Tang Swee Fong Department of Paediatrics University Kebangsaan Malaysia Medical Centre

PAEDIATRIC RESPIRATORY FAILURE. Tang Swee Fong Department of Paediatrics University Kebangsaan Malaysia Medical Centre PAEDIATRIC RESPIRATORY FAILURE Tang Swee Fong Department of Paediatrics University Kebangsaan Malaysia Medical Centre Outline of lecture Bronchiolitis Bronchopulmonary dysplasia Asthma ARDS Bronchiolitis

More information

Informed Consent for Standard of Care Research Interventions

Informed Consent for Standard of Care Research Interventions Informed Consent for Standard of Care Research Interventions Jeffrey R Botkin, MD, MPH Associate Vice President for Research A case Two FDA approved drugs are commonly used for the treatment of hypertension.

More information

Asthma Care in the Emergency Department Clinical Practice Guideline

Asthma Care in the Emergency Department Clinical Practice Guideline Asthma Care in the Emergency Department Clinical Practice Guideline Inclusion: 1) Children 2 years of age or older with a prior history of wheezing, and 2) Children less than 2 years of age with likely

More information

Tips on managing asthma in children

Tips on managing asthma in children Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma

More information

Wheezy? Easy Peasy! The Emergent Management of Asthma & Bronchiolitis. Maneesha Agarwal MD Assistant Professor of Pediatrics & Emergency Medicine

Wheezy? Easy Peasy! The Emergent Management of Asthma & Bronchiolitis. Maneesha Agarwal MD Assistant Professor of Pediatrics & Emergency Medicine Wheezy? Easy Peasy! The Emergent Management of Asthma & Bronchiolitis Maneesha Agarwal MD Assistant Professor of Pediatrics & Emergency Medicine Asthma Defined National Asthma Education and Prevention

More information

Acute Wheezing Emergencies: From Young to Old! Little Wheezers in the ED: Managing Acute Pediatric Asthma

Acute Wheezing Emergencies: From Young to Old! Little Wheezers in the ED: Managing Acute Pediatric Asthma Acute Wheezing Emergencies: From Young to Old! Little Wheezers in the ED: Managing Acute Pediatric Asthma Talk Outline Case Delivery of bronchodilators Meter-dose inhalers and spacers Continuous nebulization

More information

Online supplementary material

Online supplementary material Online supplementary material Add-on long-acting β2-agonist (LABA) in a separate inhaler as asthma step-up therapy versus increased dose of inhaled corticosteroid (ICS) or ICS/LABA combination inhaler

More information

NON INVASIVE LIFE SAVERS. Non Invasive Ventilation (NIV)

NON INVASIVE LIFE SAVERS. Non Invasive Ventilation (NIV) Table 1. NIV: Mechanisms Of Action Decreases work of breathing Increases functional residual capacity Recruits collapsed alveoli Improves respiratory gas exchange Reverses hypoventilation Maintains upper

More information

Budesonide treatment of moderate and severe asthma in children: A doseresponse

Budesonide treatment of moderate and severe asthma in children: A doseresponse Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate

More information

Minimizing Lung Damage During Respiratory Support

Minimizing Lung Damage During Respiratory Support Minimizing Lung Damage During Respiratory Support University of Miami Jackson Memorial Medical Center Care of the Sick Newborn 15 Eduardo Bancalari MD University of Miami Miller School of Medicine Jackson

More information

Omalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication

Omalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to

More information

Patient. Device Clinician. Safety & efficacy

Patient. Device Clinician. Safety & efficacy Patient Device Clinician Formulation Safety & efficacy 1. Modified from Daley-Yates et al., Expert Opin. Drug Deliv. 2011: 8(10):1297-1308 2. Modified from Laube et al., Eur Respir J 2011; 37: 1308 1331

More information

Management of Acute Asthma Exacerbations in Children 2012 Update. Sharon Kling Dept Paediatrics & Child Health University of Stellenbosch

Management of Acute Asthma Exacerbations in Children 2012 Update. Sharon Kling Dept Paediatrics & Child Health University of Stellenbosch Management of Acute Asthma Exacerbations in Children 2012 Update Sharon Kling Dept Paediatrics & Child Health University of Stellenbosch Acknowledgements BTS/SIGN guidelines GINA guidelines NAEPP guidelines

More information

Aerospan (flunisolide)

Aerospan (flunisolide) STRENGTH DOSAGE FORM ROUTE GPID 80mcg/actuation HFA aerosol inhaler w/ Inhaled 35718 8.9 g/canister adapter MANUFACTURER Meda Pharmaceuticals INDICATION Aerospan Inhalation Aerosol is indicated for the

More information

Chronic inflammation of the airways Hyperactive bronchi Shortness of breath Tightness in chest Coughing Wheezing

Chronic inflammation of the airways Hyperactive bronchi Shortness of breath Tightness in chest Coughing Wheezing Chronic inflammation of the airways Hyperactive bronchi Shortness of breath Tightness in chest Coughing Wheezing Components of the respiratory system Nasal cavity Pharynx Trachea Bronchi Bronchioles Lungs

More information

From Chronic Lung Disease of Infancy to Asthma

From Chronic Lung Disease of Infancy to Asthma From Chronic Lung Disease of Infancy to Asthma Mollie V. Anderson, CPNP Certified Pediatric Nurse Practitioner Pediatric Lung Care Bon Secours Medical Group St. Mary s Hospital 1 Mollie V. Anderson, CPNP

More information

Update on mangement of patent ductus arteriosus in preterm infants. Dr. Trinh Thi Thu Ha

Update on mangement of patent ductus arteriosus in preterm infants. Dr. Trinh Thi Thu Ha Update on mangement of patent ductus arteriosus in preterm infants Dr. Trinh Thi Thu Ha Outline 1. Overview of PDA 2. Timing of screening PDA? 3. When to treat PDA? Timing of ductal closure Prenatal

More information

Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm

Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm RESPIRATORY MEDICINE (2001) 95, 565 570 doi:10.1053/rmed.2001.1104, available online at http://www.idealibrary.com on Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm

More information

BPD. Neonatal/Pediatric Cardiopulmonary Care. Disease. Bronchopulmonary Dysplasia. Baby Jane

BPD. Neonatal/Pediatric Cardiopulmonary Care. Disease. Bronchopulmonary Dysplasia. Baby Jane 1 Neonatal/Pediatric Cardiopulmonary Care Disease 2 Bronchopulmonary Dysplasia 3 is a 33-day-old prematurely born girl who weighs 1420 g. At birth, her estimated gestational age was 28 weeks. Her initial

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Objectives. Case Presentation. Respiratory Emergencies

Objectives. Case Presentation. Respiratory Emergencies Respiratory Emergencies Objectives Describe how to assess airway and breathing, including interpreting information from the PAT and ABCDEs. Differentiate between respiratory distress, respiratory failure,

More information

A Trust Guideline for the Management of. Bronchiolitis in Infants and Children under the age of 24 months

A Trust Guideline for the Management of. Bronchiolitis in Infants and Children under the age of 24 months A Clinical Guideline recommended Children s Assessment Unit (CAU), Buxton Ward, For use in: Children s Day Ward, Jenny Lind Out-patients Department, Accident and Emergency Department By: Medical and Nursing

More information

Respiratory Care in PICU Aerosol Therapy ส พ ชชา ชา แสงโขต โรงพยาบาลสมเด จพระป นเกล า

Respiratory Care in PICU Aerosol Therapy ส พ ชชา ชา แสงโขต โรงพยาบาลสมเด จพระป นเกล า Respiratory Care in PICU Aerosol Therapy น.อ.หญ ง ส พ ชชา ชา แสงโขต โรงพยาบาลสมเด จพระป นเกล า Aerosol liquid droplets or solid particles suspended in a gas(air) visible like fog Aerosol vs Humidity Humidity

More information

Neonatal Resuscitation Using a Nasal Cannula: A Single-Center Experience

Neonatal Resuscitation Using a Nasal Cannula: A Single-Center Experience Original Article Neonatal Resuscitation Using a Nasal Cannula: A Single-Center Experience Pedro Paz, MD, MPH 1 Rangasamy Ramanathan, MD 1,2 Richard Hernandez, RCP 2 Manoj Biniwale, MD 1 1 Division of Neonatal

More information

Potential public health impact of RSV vaccines. R. Karron December 2016

Potential public health impact of RSV vaccines. R. Karron December 2016 Potential public health impact of RSV vaccines R. Karron December 2016 1. RSV is The leading cause of hospitalization in infants and in many high-income countries; >2 million medical visits annually in

More information

Discuss the benefits for developing an outpatient bronchiolitis clinic.

Discuss the benefits for developing an outpatient bronchiolitis clinic. Diana L Mark, RRT Pediatric Clinical Specialist Respiratory Care Wesley Medical Center Discuss the benefits for developing an outpatient bronchiolitis clinic. 1 Definition Inflammation of the bronchioles

More information

Outcome, classification and management of wheezing in preschool children Paul L.P. Brand

Outcome, classification and management of wheezing in preschool children Paul L.P. Brand Outcome, classification and management of wheezing in preschool children Paul L.P. Brand Princess Amalia Children s Clinic Isala klinieken, Zwolle the Netherlands p.l.p.brand@isala.nl Valle de la Luna,

More information

Supplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus

Supplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is

More information

Patent Ductus Arteriosus: Philosophy or Pathology?

Patent Ductus Arteriosus: Philosophy or Pathology? Patent Ductus Arteriosus: Philosophy or Pathology? Disclosure Ray Sato, MD is a speaker for Prolacta Biosciences, Inc. This presentation will discuss off-label uses of acetaminophen and ibuprofen. RAY

More information

PAEDIATRIC ACUTE CARE GUIDELINE. Croup. This document should be read in conjunction with this DISCLAIMER

PAEDIATRIC ACUTE CARE GUIDELINE. Croup. This document should be read in conjunction with this DISCLAIMER Princess Margaret Hospital for Children PAEDIATRIC ACUTE CARE GUIDELINE Croup Scope (Staff): Scope (Area): All Emergency Department Clinicians Emergency Department This document should be read in conjunction

More information

beclometasone 100 MDI 2 puffs twice a day (recently changed to non CFC (Clenil Modulite))

beclometasone 100 MDI 2 puffs twice a day (recently changed to non CFC (Clenil Modulite)) Case 1 Mr Thomson, a 32 year old asthmatic who is well known to you comes into your pharmacy. He is known to have a best peak flow of 640 L/min. He tells you that over the last few weeks he has been wakening

More information

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach

More information

GE Healthcare. Non Invasive Ventilation (NIV) For the Engström Ventilator. Relief, Relax, Recovery

GE Healthcare. Non Invasive Ventilation (NIV) For the Engström Ventilator. Relief, Relax, Recovery GE Healthcare Non Invasive Ventilation (NIV) For the Engström Ventilator Relief, Relax, Recovery COPD is currently the fourth leading cause of death in the world, and further increases in the prevalence

More information

Small Airways Disease. Respiratory Function In Small Airways And Asthma. Pathophysiologic Changes in the Small Airways of Asthma Patients

Small Airways Disease. Respiratory Function In Small Airways And Asthma. Pathophysiologic Changes in the Small Airways of Asthma Patients Small Airways Disease Respiratory Function In Small Airways And Relevant Questions On Small Airway Involvement In How can small airway disease be defined? What is the link between small airway abnormalities

More information

TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department

TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN Dr Lại Lê Hưng Respiratory Department Literature review current through: Feb 2013. This topic last updated: Aug 14, 2012 INTRODUCTION Wheezing

More information

Placental steroid receptors and sex differences in fetal growth

Placental steroid receptors and sex differences in fetal growth Placental steroid receptors and sex differences in fetal growth Professor Vicki Clifton Mater Medical Research Institute University of Queensland Brisbane, Australia Sex differences start in utero Lying-in

More information

Bronchiolitis (BRO) Overview

Bronchiolitis (BRO) Overview Bronchiolitis (BRO) Overview Common lower respiratory tract infection and leading cause of infant hospitalization Significant impact on the elderly with >220k hospitalizations per year in the US No drugs

More information

USE OF INHALED NITRIC OXIDE IN THE NICU East Bay Newborn Specialists Guideline Prepared by P Joe, G Dudell, A D Harlingue Revised 7/9/2014

USE OF INHALED NITRIC OXIDE IN THE NICU East Bay Newborn Specialists Guideline Prepared by P Joe, G Dudell, A D Harlingue Revised 7/9/2014 USE OF INHALED NITRIC OXIDE IN THE NICU East Bay Newborn Specialists Guideline Prepared by P Joe, G Dudell, A D Harlingue Revised 7/9/2014 ino for Late Preterm and Term Infants with Severe PPHN Background:

More information

CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) DEFINITION

CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) DEFINITION CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) DEFINITION Method of maintaining low pressure distension of lungs during inspiration and expiration when infant breathing spontaneously Benefits Improves oxygenation

More information

The University of Arizona Pediatric Residency Program. Primary Goals for Rotation. Pulmonary

The University of Arizona Pediatric Residency Program. Primary Goals for Rotation. Pulmonary The University of Arizona Pediatric Residency Program Primary Goals for Rotation Pulmonary 1. GOAL: Diagnose and manage patients with asthma. 2. GOAL: Understand the role of the pediatrician in preventing

More information

PEDIATRIC RESPIRATORY SYNCYTIAL VIRUS (RSV) ALL THAT WHEEZES IS NOT ASTHMA

PEDIATRIC RESPIRATORY SYNCYTIAL VIRUS (RSV) ALL THAT WHEEZES IS NOT ASTHMA PEDIATRIC RESPIRATORY SYNCYTIAL VIRUS (RSV) ALL THAT WHEEZES IS NOT ASTHMA Season changes here in Ohio can send the census numbers in our local P.I.C.U. s, N.I.C.U. s and Emergency Rooms through the roof.

More information

What s new in neonatal resuscitation?

What s new in neonatal resuscitation? What s new in neonatal resuscitation? Anup Katheria, M.D. Director, Neonatal Research Institute Sharp Mary Birch Hospital for Women & Newborns Disclosures I have no financial Disclosures. Overview Delivery

More information

MASTER SYLLABUS

MASTER SYLLABUS MASTER SYLLABUS 2018-2019 A. Academic Division: Health Science B. Discipline: Respiratory Care C. Course Number and Title: RESP 2490 Practicum IV D. Course Coordinator: Tricia Winters, BBA, RRT, RCP Assistant

More information

Neonatal Resuscitation in What is new? How did we get here? Steven Ringer MD PhD Harvard Medical School May 25, 2011

Neonatal Resuscitation in What is new? How did we get here? Steven Ringer MD PhD Harvard Medical School May 25, 2011 Neonatal Resuscitation in 2011- What is new? How did we get here? Steven Ringer MD PhD Harvard Medical School May 25, 2011 Conflicts I have no actual or potential conflict of interest in relation to this

More information

Systems differ in their ability to deliver optimal humidification

Systems differ in their ability to deliver optimal humidification Average Absolute Humidity (mg H 2 O/L) Systems differ in their ability to deliver optimal humidification 45 Flows Tested 40 35 30 Optiflow Airvo 2 Vapotherm Vapotherm 5 L/min 10L/min 20L/min 30L/min 40L/min

More information

Newborn Life Support. NLS guidance.

Newborn Life Support. NLS guidance. Kelly Harvey, ANNP NWNODN, previously Wythenshawe Hospital has shared this presentation with the understanding that it is for personal use following your attendance at the 8th Annual Senior Neonatal Nursing

More information

Preschool Asthma What you need to know in 10 minutes

Preschool Asthma What you need to know in 10 minutes Preschool Asthma What you need to know in 10 minutes Alan Kaplan MD CCFP(EM) FCFP Family Physician Airways Group of Canada Respiratory Medicine section CFPC Faculty/Presenter Disclosure Faculty: Alan Kaplan

More information

PEDIATRIC ACUTE ASTHMA SCORE (P.A.A.S.) GUIDELINES. >97% 94% to 96% 91%-93% <90% Moderate to severe expiratory wheeze

PEDIATRIC ACUTE ASTHMA SCORE (P.A.A.S.) GUIDELINES. >97% 94% to 96% 91%-93% <90% Moderate to severe expiratory wheeze Inclusion: Children experiencing acute asthma exacerbation 24 months to 18 years of age with a diagnosis of asthma Patients with a previous history of asthma (Consider differential diagnosis for infants

More information

Late pulmonary hypertension in preterm infants How to sort things out? V.Gournay, FCPC, La Martinique, Nov 23,2015

Late pulmonary hypertension in preterm infants How to sort things out? V.Gournay, FCPC, La Martinique, Nov 23,2015 Late pulmonary hypertension in preterm infants How to sort things out? V.Gournay, FCPC, La Martinique, Nov 23,2015 Epidemiology Incidence of extreme prematurity (

More information

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH

More information

AllergyANDClinical Immunology

AllergyANDClinical Immunology THE JOURNAL OF AllergyANDClinical Immunology VOLUME 106 NUMBER 6 OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY New products Series editors: Donald Y. M. Leung, MD, PhD, Harold

More information

Evaluation of the Local Incidence and Determinants of Bronchopulmonary Dysplasia and Pulmonary Morbidity in Extremely Preterm Infants

Evaluation of the Local Incidence and Determinants of Bronchopulmonary Dysplasia and Pulmonary Morbidity in Extremely Preterm Infants Evaluation of the Local Incidence and Determinants of Bronchopulmonary Dysplasia and Pulmonary Morbidity in Extremely Preterm Infants by Amber Elise Reichert A thesis submitted in partial fulfilment of

More information

Emergency Medicine High Velocity Nasal Insufflation (Hi-VNI) VAPOTHERM POCKET GUIDE

Emergency Medicine High Velocity Nasal Insufflation (Hi-VNI) VAPOTHERM POCKET GUIDE Emergency Medicine High Velocity Nasal Insufflation (Hi-VNI) VAPOTHERM POCKET GUIDE Indications for Vapotherm High Velocity Nasal Insufflation (Hi-VNI ) administration, the patient should be: Spontaneously

More information

10/13/2017. Newborn Care. Objectives. Cardiac Anatomy. Managing Transitional Physiology

10/13/2017. Newborn Care. Objectives. Cardiac Anatomy. Managing Transitional Physiology Newborn Care Managing Transitional Physiology Mary Coughlin MS, NNP, RNC-E President and Founder Caring Essentials Collaborative Boston, MA Objectives Upon completion of the learning session participants

More information

Annex II. Scientific conclusions

Annex II. Scientific conclusions Annex II Scientific conclusions 5 Scientific conclusions Beclometasone dipropionate (BDP) is a glucocorticoid and a prodrug of the active metabolite, beclometasone-17-monopropionate. Beclometasone dipropionate

More information

Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants(review)

Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants(review) Cochrane Database of Systematic Reviews Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants (Review) SubramaniamP,HoJJ,DavisPG Subramaniam

More information

Steven Ringer MD PhD April 5, 2011

Steven Ringer MD PhD April 5, 2011 Steven Ringer MD PhD April 5, 2011 Disclaimer Mead Johnson sponsors programs such as this to give healthcare professionals access to scientific and educational information provided by experts. The presenter

More information

ROLE OF EARLY POSTNATAL DEXAMETHASONE IN RESPIRATORY DISTRESS SYNDROME

ROLE OF EARLY POSTNATAL DEXAMETHASONE IN RESPIRATORY DISTRESS SYNDROME INDIAN PEDIATRICS VOLUME 35-FEBRUAKY 1998 ROLE OF EARLY POSTNATAL DEXAMETHASONE IN RESPIRATORY DISTRESS SYNDROME Kanya Mukhopadhyay, Praveen Kumar and Anil Narang From the Division of Neonatology, Department

More information

PEDIATRIC ASTHMA INPATIENT CARE MAP

PEDIATRIC ASTHMA INPATIENT CARE MAP DATE PATIENT PEDIATRIC ASTHMA INPATIENT CARE MAP DOB HSC NO. PHIN Approved by the Winnipeg Regional Health Authority This Care Map is to be used as a guideline and in no way replaces sound clinical judgment

More information

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma

More information

Asthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?

Asthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP? 10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher

More information

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Chronic Obstructive Pulmonary Disease (COPD) Measures Document

Chronic Obstructive Pulmonary Disease (COPD) Measures Document Chronic Obstructive Pulmonary Disease (COPD) Measures Document COPD Version: 3 - covering patients discharged between 01/10/2017 and present. Programme Lead: Jo Higgins Clinical Lead: Dr Paul Albert Number

More information

Home Pulse Oximetry for Infants and Children

Home Pulse Oximetry for Infants and Children Last Review Date: April 21, 2017 Number: MG.MM.DM.12aC2v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

Best of Pulmonary Jennifer R. Hucks, MD University of South Carolina School of Medicine

Best of Pulmonary Jennifer R. Hucks, MD University of South Carolina School of Medicine Best of Pulmonary 2012-2013 Jennifer R. Hucks, MD University of South Carolina School of Medicine Topics ARDS- Berlin Definition Prone Positioning For ARDS Lung Protective Ventilation In Patients Without

More information

Research Roundtable Summary

Research Roundtable Summary Research Roundtable Summary 10 TENTH in a Series of Seminars on MCHB-funded Research Projects Early Cortisol Deficiency and Bronchopulmonary Dysplasia October 18, 1995 Parklawn Building Potomac Conference

More information

The FDA Critical Path Initiative

The FDA Critical Path Initiative The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary

More information

SEDATION FOR SMALL PROCEDURES

SEDATION FOR SMALL PROCEDURES SEDATION FOR SMALL PROCEDURES Sinno Simons Erasmus MC Sophia Children s Hospital Rotterdam, the Netherlands s.simons@erasmusmc.nl SEDATION in newborns How and when How to evaluate How to dose Why to use

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Disclosures. Learning Objectives. Mechanical Ventilation of Infants with Severe BPD: An Interdisciplinary Approach 3/10/2017

Disclosures. Learning Objectives. Mechanical Ventilation of Infants with Severe BPD: An Interdisciplinary Approach 3/10/2017 Mechanical Ventilation of Infants with Severe BPD: An Interdisciplinary Approach Steven H. Abman, MD Professor, Department of Pediatrics Director, Pediatric Heart Lung Center University of Colorado School

More information

Surfactant Administration

Surfactant Administration Approved by: Surfactant Administration Gail Cameron Senior Director Operations, Maternal, Neonatal & Child Health Programs Dr. Paul Byrne Medical Director, Neonatology Neonatal Policy & Procedures Manual

More information

** SURFACTANT THERAPY**

** SURFACTANT THERAPY** ** SURFACTANT THERAPY** Full Title of Guideline: Surfactant Therapy Author (include email and role): Stephen Wardle (V4) Reviewed by Dushyant Batra Consultant Neonatologist Division & Speciality: Division:

More information

Starship Paediatric Respiratory and Sleep Medicine Department Outpatient Referral Criteria General Principles

Starship Paediatric Respiratory and Sleep Medicine Department Outpatient Referral Criteria General Principles Starship Paediatric Respiratory and Sleep Medicine Department Outpatient Referral Criteria General Principles This document provides guidance for elective outpatient referrals to the Starship Tertiary

More information

An update on childhood sleep-disordered breathing

An update on childhood sleep-disordered breathing An update on childhood sleep-disordered breathing แพทย หญ งวนพร อน นตเสร ภาคว ชาก มารเวชศาสตร คณะแพทยศาสตร มหาว ทยาล ยสงขลานคร นทร Sleep-disordered breathing Primary snoring Upper airway resistance syndrome

More information

POLICY. Number: Title: APPLICATION OF NON INVASIVE VENTILATION FOR ACUTE RESPIRATORY FAILURE. Authorization

POLICY. Number: Title: APPLICATION OF NON INVASIVE VENTILATION FOR ACUTE RESPIRATORY FAILURE. Authorization POLICY Number: 7311-60-024 Title: APPLICATION OF NON INVASIVE VENTILATION FOR ACUTE RESPIRATORY FAILURE Authorization [ ] President and CEO [ x ] Vice President, Finance and Corporate Services Source:

More information